Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pemphigoid, Bullous | 6 | 2022 | 110 | 3.480 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 9 | 2022 | 207 | 3.140 |
Why?
|
Skin Neoplasms | 30 | 2023 | 5691 | 2.950 |
Why?
|
Exanthema | 5 | 2024 | 501 | 2.540 |
Why?
|
Drug Eruptions | 8 | 2022 | 297 | 2.390 |
Why?
|
Scleroderma, Localized | 2 | 2023 | 79 | 1.590 |
Why?
|
Skin | 22 | 2024 | 4372 | 1.550 |
Why?
|
Lupus Erythematosus, Cutaneous | 3 | 2020 | 58 | 1.460 |
Why?
|
Paget Disease, Extramammary | 2 | 2021 | 45 | 1.410 |
Why?
|
Histiocytosis, Langerhans-Cell | 2 | 2021 | 171 | 1.330 |
Why?
|
Lymphoproliferative Disorders | 2 | 2022 | 524 | 1.300 |
Why?
|
Mycosis Fungoides | 6 | 2023 | 163 | 1.300 |
Why?
|
Skin Diseases | 7 | 2023 | 1066 | 1.260 |
Why?
|
Melanoma | 12 | 2023 | 5508 | 1.200 |
Why?
|
Lymphomatoid Papulosis | 2 | 2017 | 16 | 1.120 |
Why?
|
Neoplasms | 23 | 2024 | 21675 | 1.020 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 2 | 2017 | 169 | 0.950 |
Why?
|
Oncolytic Virotherapy | 4 | 2023 | 498 | 0.940 |
Why?
|
Pentoxifylline | 1 | 2023 | 55 | 0.920 |
Why?
|
Stomatitis, Aphthous | 1 | 2023 | 53 | 0.900 |
Why?
|
Behcet Syndrome | 1 | 2023 | 84 | 0.870 |
Why?
|
Acitretin | 1 | 2022 | 14 | 0.860 |
Why?
|
Sezary Syndrome | 2 | 2019 | 76 | 0.830 |
Why?
|
Dermatomyositis | 2 | 2020 | 224 | 0.770 |
Why?
|
Mechlorethamine | 1 | 2020 | 136 | 0.750 |
Why?
|
Genital Neoplasms, Male | 1 | 2021 | 74 | 0.750 |
Why?
|
Myeloproliferative Disorders | 4 | 2020 | 606 | 0.720 |
Why?
|
Sterilization | 1 | 2021 | 133 | 0.720 |
Why?
|
Fasciitis | 1 | 2020 | 65 | 0.720 |
Why?
|
Alkylating Agents | 1 | 2020 | 139 | 0.720 |
Why?
|
Edema | 2 | 2023 | 789 | 0.710 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2021 | 188 | 0.700 |
Why?
|
Calciphylaxis | 1 | 2021 | 124 | 0.670 |
Why?
|
Protein Kinase Inhibitors | 6 | 2024 | 5532 | 0.660 |
Why?
|
Quinoxalines | 1 | 2021 | 289 | 0.660 |
Why?
|
Pityriasis Rubra Pilaris | 1 | 2018 | 12 | 0.650 |
Why?
|
Dermatitis, Exfoliative | 1 | 2018 | 28 | 0.650 |
Why?
|
Immunotherapy | 17 | 2024 | 4437 | 0.620 |
Why?
|
Brachytherapy | 3 | 2021 | 1247 | 0.620 |
Why?
|
Cancer Care Facilities | 1 | 2020 | 402 | 0.610 |
Why?
|
Hydrogen Peroxide | 1 | 2021 | 730 | 0.590 |
Why?
|
Alopecia | 2 | 2020 | 382 | 0.580 |
Why?
|
Boron Compounds | 1 | 2018 | 175 | 0.570 |
Why?
|
Antineoplastic Agents | 14 | 2024 | 13691 | 0.560 |
Why?
|
Eosinophilia | 1 | 2020 | 541 | 0.550 |
Why?
|
Dendritic Cells | 5 | 2023 | 2720 | 0.540 |
Why?
|
Acneiform Eruptions | 1 | 2014 | 4 | 0.510 |
Why?
|
Facial Dermatoses | 1 | 2015 | 87 | 0.490 |
Why?
|
Carcinoma, Merkel Cell | 2 | 2015 | 303 | 0.490 |
Why?
|
Glycine | 1 | 2018 | 670 | 0.490 |
Why?
|
Humans | 112 | 2024 | 743811 | 0.490 |
Why?
|
Pyrazoles | 2 | 2024 | 1970 | 0.480 |
Why?
|
Facial Neoplasms | 1 | 2015 | 121 | 0.480 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2023 | 2453 | 0.470 |
Why?
|
Psoriasis | 1 | 2022 | 901 | 0.470 |
Why?
|
Vitiligo | 3 | 2024 | 89 | 0.470 |
Why?
|
Pruritus | 1 | 2017 | 361 | 0.460 |
Why?
|
Vasculitis | 1 | 2018 | 519 | 0.460 |
Why?
|
Morpholines | 1 | 2017 | 571 | 0.460 |
Why?
|
Pyridazines | 1 | 2015 | 202 | 0.460 |
Why?
|
Carcinoid Tumor | 1 | 2015 | 235 | 0.450 |
Why?
|
Granuloma | 1 | 2015 | 319 | 0.430 |
Why?
|
Retrospective Studies | 28 | 2024 | 77410 | 0.410 |
Why?
|
Carcinoma, Squamous Cell | 6 | 2023 | 4033 | 0.390 |
Why?
|
Respiratory Protective Devices | 2 | 2021 | 45 | 0.390 |
Why?
|
Guideline Adherence | 1 | 2020 | 2265 | 0.360 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 4848 | 0.350 |
Why?
|
Immunocompromised Host | 3 | 2011 | 847 | 0.340 |
Why?
|
Biopsy | 6 | 2022 | 6750 | 0.340 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1063 | 0.330 |
Why?
|
Imidazoles | 1 | 2015 | 1206 | 0.330 |
Why?
|
Paraneoplastic Syndromes | 2 | 2024 | 151 | 0.330 |
Why?
|
Sebaceous Gland Diseases | 1 | 2007 | 5 | 0.320 |
Why?
|
Lung Neoplasms | 5 | 2024 | 13112 | 0.310 |
Why?
|
Administration, Cutaneous | 4 | 2023 | 710 | 0.300 |
Why?
|
Dermatitis, Irritant | 2 | 2020 | 17 | 0.300 |
Why?
|
Polyendocrinopathies, Autoimmune | 1 | 2007 | 55 | 0.290 |
Why?
|
Breast Neoplasms | 7 | 2024 | 20827 | 0.290 |
Why?
|
Aged | 28 | 2024 | 163178 | 0.290 |
Why?
|
Radioimmunotherapy | 2 | 2024 | 91 | 0.290 |
Why?
|
Adrenal Cortex Hormones | 2 | 2020 | 1854 | 0.290 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2015 | 991 | 0.290 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2014 | 1100 | 0.290 |
Why?
|
Thigh | 2 | 2021 | 247 | 0.290 |
Why?
|
Herpes Simplex | 1 | 2010 | 470 | 0.280 |
Why?
|
Head and Neck Neoplasms | 1 | 2020 | 2736 | 0.280 |
Why?
|
Administration, Topical | 2 | 2020 | 689 | 0.270 |
Why?
|
Hamartoma | 1 | 2007 | 238 | 0.260 |
Why?
|
Nevus, Pigmented | 1 | 2007 | 219 | 0.260 |
Why?
|
Female | 35 | 2024 | 380020 | 0.230 |
Why?
|
Male | 38 | 2023 | 349776 | 0.220 |
Why?
|
Erythema Multiforme | 1 | 2022 | 31 | 0.210 |
Why?
|
Diagnosis, Differential | 5 | 2020 | 12954 | 0.200 |
Why?
|
Stevens-Johnson Syndrome | 2 | 2022 | 281 | 0.200 |
Why?
|
Hematologic Neoplasms | 3 | 2020 | 1832 | 0.200 |
Why?
|
Middle Aged | 25 | 2024 | 213241 | 0.200 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2023 | 134 | 0.200 |
Why?
|
Enterocolitis | 1 | 2022 | 102 | 0.200 |
Why?
|
Dermatology | 2 | 2022 | 872 | 0.200 |
Why?
|
Equipment Reuse | 1 | 2021 | 41 | 0.190 |
Why?
|
Molecular Targeted Therapy | 4 | 2020 | 2727 | 0.190 |
Why?
|
Biological Therapy | 1 | 2022 | 138 | 0.190 |
Why?
|
Myasthenia Gravis | 1 | 2023 | 199 | 0.190 |
Why?
|
Lymphoma, T-Cell | 1 | 2023 | 299 | 0.190 |
Why?
|
Gastritis | 1 | 2022 | 196 | 0.190 |
Why?
|
Decontamination | 1 | 2021 | 69 | 0.190 |
Why?
|
Sulfonamides | 3 | 2016 | 1938 | 0.190 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6773 | 0.190 |
Why?
|
Dermatitis | 1 | 2022 | 199 | 0.190 |
Why?
|
Myositis | 1 | 2023 | 251 | 0.180 |
Why?
|
Dermatitis, Occupational | 1 | 2020 | 27 | 0.180 |
Why?
|
Aged, 80 and over | 13 | 2022 | 57744 | 0.180 |
Why?
|
Equipment and Supplies, Hospital | 1 | 2020 | 57 | 0.180 |
Why?
|
Histamine Antagonists | 1 | 2020 | 93 | 0.180 |
Why?
|
Practice Guidelines as Topic | 4 | 2021 | 7270 | 0.180 |
Why?
|
Consensus | 3 | 2024 | 2954 | 0.180 |
Why?
|
Case-Control Studies | 4 | 2022 | 21733 | 0.180 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2020 | 5445 | 0.180 |
Why?
|
Eczema | 1 | 2022 | 231 | 0.180 |
Why?
|
Combined Modality Therapy | 3 | 2023 | 8637 | 0.180 |
Why?
|
Cytotoxins | 1 | 2020 | 153 | 0.170 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2022 | 4386 | 0.170 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2023 | 2039 | 0.170 |
Why?
|
Antibodies, Antinuclear | 1 | 2020 | 326 | 0.170 |
Why?
|
Quality of Life | 5 | 2024 | 12788 | 0.160 |
Why?
|
Purpura Fulminans | 1 | 2018 | 22 | 0.160 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2023 | 379 | 0.160 |
Why?
|
Nitriles | 1 | 2024 | 953 | 0.160 |
Why?
|
Penile Neoplasms | 1 | 2020 | 161 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2019 | 193 | 0.160 |
Why?
|
Disease Management | 2 | 2020 | 2459 | 0.160 |
Why?
|
Bandages | 1 | 2020 | 266 | 0.160 |
Why?
|
Upper Extremity | 1 | 2023 | 647 | 0.160 |
Why?
|
Protein C | 1 | 2018 | 138 | 0.160 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2018 | 71 | 0.160 |
Why?
|
Thrombomodulin | 1 | 2018 | 102 | 0.160 |
Why?
|
Ultraviolet Rays | 1 | 2023 | 1060 | 0.160 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2020 | 3591 | 0.160 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2019 | 323 | 0.160 |
Why?
|
Scalp | 1 | 2020 | 378 | 0.150 |
Why?
|
Stomatitis | 1 | 2020 | 267 | 0.150 |
Why?
|
Arthritis, Rheumatoid | 2 | 2023 | 3712 | 0.150 |
Why?
|
Mouth | 1 | 2020 | 374 | 0.150 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 412 | 0.140 |
Why?
|
Oligodendroglioma | 1 | 2018 | 279 | 0.140 |
Why?
|
Pancreatitis | 1 | 2023 | 1092 | 0.140 |
Why?
|
Withholding Treatment | 1 | 2020 | 599 | 0.140 |
Why?
|
Glucocorticoids | 2 | 2022 | 2107 | 0.140 |
Why?
|
Treatment Outcome | 10 | 2022 | 63042 | 0.140 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2020 | 640 | 0.140 |
Why?
|
Pityriasis | 1 | 2015 | 10 | 0.140 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2023 | 3524 | 0.140 |
Why?
|
Substance P | 1 | 2017 | 335 | 0.130 |
Why?
|
Myocarditis | 1 | 2023 | 768 | 0.130 |
Why?
|
Cell Death | 2 | 2023 | 1705 | 0.130 |
Why?
|
Immunologic Factors | 3 | 2023 | 1580 | 0.130 |
Why?
|
Cohort Studies | 9 | 2024 | 40545 | 0.130 |
Why?
|
Folliculitis | 1 | 2015 | 28 | 0.130 |
Why?
|
Epidermolysis Bullosa Dystrophica | 1 | 2015 | 26 | 0.130 |
Why?
|
Bile Duct Neoplasms | 1 | 2021 | 567 | 0.130 |
Why?
|
Prognosis | 7 | 2020 | 29052 | 0.130 |
Why?
|
Cholangiocarcinoma | 1 | 2021 | 516 | 0.130 |
Why?
|
Adult | 17 | 2023 | 213889 | 0.130 |
Why?
|
Tissue Banks | 1 | 2016 | 184 | 0.130 |
Why?
|
Ichthyosis | 1 | 2015 | 60 | 0.130 |
Why?
|
Urogenital Neoplasms | 1 | 2016 | 137 | 0.130 |
Why?
|
Benzoyl Peroxide | 1 | 2014 | 18 | 0.130 |
Why?
|
Hypothermia, Induced | 1 | 2020 | 752 | 0.130 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 890 | 0.120 |
Why?
|
Indoles | 2 | 2014 | 1841 | 0.120 |
Why?
|
Xanthomatosis | 1 | 2014 | 32 | 0.120 |
Why?
|
Colitis | 1 | 2022 | 1170 | 0.120 |
Why?
|
Clindamycin | 1 | 2014 | 139 | 0.120 |
Why?
|
Antirheumatic Agents | 1 | 2023 | 1338 | 0.120 |
Why?
|
Antimalarials | 1 | 2020 | 904 | 0.120 |
Why?
|
Minocycline | 1 | 2014 | 163 | 0.110 |
Why?
|
Hidradenitis Suppurativa | 1 | 2016 | 153 | 0.110 |
Why?
|
Taxoids | 1 | 2016 | 666 | 0.110 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2023 | 2942 | 0.110 |
Why?
|
Clone Cells | 3 | 2023 | 1692 | 0.110 |
Why?
|
Urologic Neoplasms | 1 | 2016 | 318 | 0.110 |
Why?
|
Radiotherapy | 1 | 2019 | 1533 | 0.110 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 941 | 0.100 |
Why?
|
Keratoacanthoma | 1 | 2012 | 33 | 0.100 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1781 | 0.100 |
Why?
|
Antibodies, Monoclonal | 5 | 2023 | 9272 | 0.100 |
Why?
|
Pyrimidines | 1 | 2024 | 2945 | 0.100 |
Why?
|
Biological Products | 1 | 2020 | 859 | 0.100 |
Why?
|
Chlorhexidine | 1 | 2013 | 160 | 0.100 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2016 | 3547 | 0.100 |
Why?
|
T-Lymphocyte Subsets | 1 | 2019 | 1837 | 0.100 |
Why?
|
Acanthamoeba | 1 | 2010 | 13 | 0.100 |
Why?
|
Skin Diseases, Parasitic | 1 | 2010 | 13 | 0.100 |
Why?
|
Evidence-Based Medicine | 2 | 2020 | 3608 | 0.100 |
Why?
|
Amebiasis | 1 | 2010 | 34 | 0.100 |
Why?
|
Leukemia | 2 | 2016 | 1509 | 0.100 |
Why?
|
Occupational Exposure | 1 | 2021 | 1787 | 0.100 |
Why?
|
Nervous System Diseases | 1 | 2021 | 1619 | 0.090 |
Why?
|
Anti-Infective Agents, Local | 1 | 2013 | 250 | 0.090 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 689 | 0.090 |
Why?
|
Lymphoma | 2 | 2016 | 1875 | 0.090 |
Why?
|
Catheter-Related Infections | 1 | 2013 | 252 | 0.090 |
Why?
|
Survival Rate | 3 | 2021 | 12786 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 1434 | 0.090 |
Why?
|
Astrocytoma | 1 | 2014 | 790 | 0.090 |
Why?
|
Mutation | 6 | 2023 | 29777 | 0.090 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2015 | 646 | 0.080 |
Why?
|
Paclitaxel | 1 | 2016 | 1705 | 0.080 |
Why?
|
Phototherapy | 2 | 2023 | 377 | 0.080 |
Why?
|
T-Lymphocytes | 3 | 2022 | 10179 | 0.080 |
Why?
|
Medical Oncology | 1 | 2020 | 2267 | 0.080 |
Why?
|
Pandemics | 4 | 2021 | 8385 | 0.080 |
Why?
|
Transplantation Conditioning | 1 | 2015 | 1599 | 0.080 |
Why?
|
Eyelashes | 1 | 2007 | 16 | 0.080 |
Why?
|
Immunosuppressive Agents | 4 | 2016 | 4152 | 0.080 |
Why?
|
Keratosis, Seborrheic | 1 | 2007 | 27 | 0.080 |
Why?
|
Massachusetts | 1 | 2020 | 8660 | 0.080 |
Why?
|
Eyebrows | 1 | 2007 | 28 | 0.080 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 1596 | 0.070 |
Why?
|
Lymphocytes | 1 | 2015 | 2615 | 0.070 |
Why?
|
Risk Factors | 4 | 2023 | 72252 | 0.070 |
Why?
|
Fatal Outcome | 2 | 2010 | 1851 | 0.070 |
Why?
|
Disease-Free Survival | 1 | 2017 | 6895 | 0.070 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 2 | 2019 | 343 | 0.070 |
Why?
|
Nails | 1 | 2007 | 292 | 0.070 |
Why?
|
Photochemotherapy | 1 | 2012 | 808 | 0.070 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2011 | 1770 | 0.070 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 5230 | 0.060 |
Why?
|
Immunologic Memory | 1 | 2012 | 1347 | 0.060 |
Why?
|
Ligands | 2 | 2022 | 3281 | 0.060 |
Why?
|
Receptor, erbB-2 | 1 | 2014 | 2418 | 0.060 |
Why?
|
Protein Binding | 1 | 2017 | 9377 | 0.060 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2012 | 1821 | 0.060 |
Why?
|
Radiography | 1 | 2015 | 7010 | 0.060 |
Why?
|
Electronic Health Records | 1 | 2020 | 4467 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 11524 | 0.060 |
Why?
|
United States | 2 | 2021 | 69859 | 0.050 |
Why?
|
Ultrasonography | 1 | 2015 | 5986 | 0.050 |
Why?
|
MutS Homolog 2 Protein | 1 | 2023 | 200 | 0.050 |
Why?
|
Adolescent | 4 | 2022 | 85729 | 0.050 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2023 | 424 | 0.050 |
Why?
|
Medicare | 1 | 2020 | 6565 | 0.050 |
Why?
|
Survival Analysis | 3 | 2020 | 10251 | 0.050 |
Why?
|
DNA-Binding Proteins | 1 | 2019 | 9648 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 9239 | 0.050 |
Why?
|
Cell Lineage | 2 | 2023 | 2506 | 0.050 |
Why?
|
Containment of Biohazards | 1 | 2020 | 37 | 0.050 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2024 | 539 | 0.050 |
Why?
|
Aminopyridines | 1 | 2024 | 543 | 0.040 |
Why?
|
Injections, Intralesional | 1 | 2020 | 276 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2023 | 426 | 0.040 |
Why?
|
Delphi Technique | 1 | 2022 | 777 | 0.040 |
Why?
|
Liver Transplantation | 1 | 2010 | 2119 | 0.040 |
Why?
|
Endocrine System | 1 | 2020 | 113 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39001 | 0.040 |
Why?
|
Capnocytophaga | 1 | 2018 | 26 | 0.040 |
Why?
|
Transcription Factors | 1 | 2019 | 12209 | 0.040 |
Why?
|
Ventilators, Mechanical | 1 | 2021 | 292 | 0.040 |
Why?
|
Masks | 1 | 2021 | 197 | 0.040 |
Why?
|
Disinfection | 1 | 2021 | 191 | 0.040 |
Why?
|
Cell Line, Tumor | 3 | 2023 | 16674 | 0.040 |
Why?
|
Child | 3 | 2022 | 77637 | 0.040 |
Why?
|
Organ Specificity | 1 | 2023 | 2008 | 0.040 |
Why?
|
Disease Progression | 3 | 2022 | 13273 | 0.040 |
Why?
|
Graft vs Host Disease | 1 | 2010 | 2958 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 10940 | 0.040 |
Why?
|
Transplantation, Homologous | 2 | 2016 | 4777 | 0.040 |
Why?
|
Young Adult | 2 | 2020 | 56392 | 0.040 |
Why?
|
Oncolytic Viruses | 1 | 2020 | 327 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 841 | 0.040 |
Why?
|
Time-Lapse Imaging | 1 | 2017 | 195 | 0.040 |
Why?
|
Radiodermatitis | 1 | 2016 | 60 | 0.040 |
Why?
|
E-Selectin | 1 | 2018 | 579 | 0.030 |
Why?
|
Nail Diseases | 1 | 2016 | 51 | 0.030 |
Why?
|
Pigmentation Disorders | 1 | 2016 | 101 | 0.030 |
Why?
|
Abdominal Pain | 1 | 2022 | 1064 | 0.030 |
Why?
|
Endothelium | 1 | 2018 | 777 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 246 | 0.030 |
Why?
|
Collagen Type VII | 1 | 2015 | 20 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2017 | 348 | 0.030 |
Why?
|
Diarrhea | 1 | 2022 | 1348 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 2023 | 2509 | 0.030 |
Why?
|
Herpesvirus 1, Human | 1 | 2020 | 743 | 0.030 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2018 | 954 | 0.030 |
Why?
|
SEER Program | 1 | 2020 | 1507 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 1787 | 0.030 |
Why?
|
Neoplasm Staging | 3 | 2014 | 11036 | 0.030 |
Why?
|
Myeloablative Agonists | 1 | 2015 | 218 | 0.030 |
Why?
|
Busulfan | 1 | 2015 | 263 | 0.030 |
Why?
|
Isoquinolines | 1 | 2016 | 364 | 0.030 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 222 | 0.030 |
Why?
|
Face | 1 | 2020 | 993 | 0.030 |
Why?
|
Transplantation Immunology | 1 | 2016 | 546 | 0.030 |
Why?
|
Vidarabine | 1 | 2015 | 345 | 0.030 |
Why?
|
Neurotoxicity Syndromes | 1 | 2017 | 290 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 755 | 0.030 |
Why?
|
Heterozygote | 1 | 2020 | 2803 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 381 | 0.030 |
Why?
|
Triage | 1 | 2020 | 977 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2020 | 2879 | 0.030 |
Why?
|
Occlusive Dressings | 1 | 2013 | 50 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2014 | 8856 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8430 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2017 | 1880 | 0.030 |
Why?
|
Geriatric Assessment | 1 | 2020 | 1372 | 0.030 |
Why?
|
Acute Disease | 1 | 2023 | 7150 | 0.030 |
Why?
|
Valine | 1 | 2014 | 413 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2085 | 0.030 |
Why?
|
Pyridines | 1 | 2024 | 2827 | 0.030 |
Why?
|
Survivors | 1 | 2022 | 2291 | 0.030 |
Why?
|
Polyomavirus Infections | 1 | 2014 | 200 | 0.030 |
Why?
|
Mice | 4 | 2023 | 81154 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1876 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2429 | 0.020 |
Why?
|
Aminolevulinic Acid | 1 | 2012 | 142 | 0.020 |
Why?
|
Tumor Virus Infections | 1 | 2014 | 454 | 0.020 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2017 | 828 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2019 | 1937 | 0.020 |
Why?
|
Gene Expression | 1 | 2023 | 7793 | 0.020 |
Why?
|
Infant | 3 | 2020 | 35122 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2560 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2017 | 1677 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2023 | 4477 | 0.020 |
Why?
|
Patient Care Team | 1 | 2021 | 2528 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2017 | 6311 | 0.020 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2014 | 710 | 0.020 |
Why?
|
Glutamic Acid | 1 | 2014 | 1168 | 0.020 |
Why?
|
Catheterization, Central Venous | 1 | 2013 | 514 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2012 | 604 | 0.020 |
Why?
|
Frontal Lobe | 1 | 2014 | 1395 | 0.020 |
Why?
|
Photosensitizing Agents | 1 | 2012 | 602 | 0.020 |
Why?
|
Pilot Projects | 1 | 2020 | 8316 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2017 | 5973 | 0.020 |
Why?
|
Health Personnel | 1 | 2020 | 3217 | 0.020 |
Why?
|
Temporal Lobe | 1 | 2014 | 1656 | 0.020 |
Why?
|
Animals | 4 | 2023 | 168660 | 0.020 |
Why?
|
Cell Survival | 1 | 2016 | 5881 | 0.020 |
Why?
|
Phenotype | 2 | 2016 | 16361 | 0.020 |
Why?
|
Hospitals | 1 | 2020 | 3953 | 0.020 |
Why?
|
Immune System | 1 | 2012 | 807 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4931 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1794 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10380 | 0.020 |
Why?
|
Societies, Medical | 1 | 2017 | 3740 | 0.020 |
Why?
|
Piperazines | 1 | 2016 | 2487 | 0.020 |
Why?
|
Fibroblasts | 1 | 2015 | 4162 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5319 | 0.020 |
Why?
|
Incidence | 1 | 2023 | 20948 | 0.020 |
Why?
|
Recurrence | 1 | 2016 | 8337 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12243 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2023 | 18027 | 0.020 |
Why?
|
Child, Preschool | 2 | 2020 | 40964 | 0.010 |
Why?
|
Logistic Models | 1 | 2019 | 13404 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2017 | 11360 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 2012 | 1988 | 0.010 |
Why?
|
Glycoproteins | 1 | 2012 | 2266 | 0.010 |
Why?
|
Internet | 1 | 2016 | 3058 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3706 | 0.010 |
Why?
|
Anticoagulants | 1 | 2018 | 4599 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2015 | 3690 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2017 | 5170 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2016 | 2988 | 0.010 |
Why?
|
Cytokines | 1 | 2017 | 7324 | 0.010 |
Why?
|
Organ Transplantation | 1 | 2013 | 1140 | 0.010 |
Why?
|
Lung | 1 | 2020 | 9858 | 0.010 |
Why?
|
Antigens, CD | 1 | 2012 | 4026 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2016 | 10477 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2010 | 6487 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 5983 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2015 | 13028 | 0.010 |
Why?
|
Critical Illness | 1 | 2013 | 2670 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2016 | 9440 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 9944 | 0.010 |
Why?
|
Neutrophils | 1 | 2012 | 3718 | 0.010 |
Why?
|
Sepsis | 1 | 2013 | 2593 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 17439 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15526 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 6237 | 0.010 |
Why?
|
Graft Rejection | 1 | 2010 | 4398 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2014 | 35409 | 0.010 |
Why?
|
Prospective Studies | 1 | 2019 | 53250 | 0.010 |
Why?
|